What is the main business of Biovirtus?

The main business activity of Biovirtus focuses on research and experimental development in natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on February 27, 2017.

Where is the headquarters located?

The headquarters is located at: ul. Augustyna Locciego 5, 00-582 Warszawa.

What is the share capital?

The share capital of the company is PLN 100,000 (approx. $27,012).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What was the revenue?

The company reported a revenue of $65 in 2025, which is a decrease of 11.8% compared to 2024.

No, the company recorded a net loss of $440 in 2025. For comparison, in 2024 the loss was $106, meaning the company increased its loss by 312.2%.

What is the main operating cost?

The largest operating cost category falls under external services. This category amounted to $105 in 2025, representing 100% of all operating expenses.

Biovirtussp. z o.o. in liquidation

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2017-02-27

Share capital

100,000.00 PLN

Registered address

ul. Augustyna Locciego 5/2, 00-582 Warszawa, Poland

Financials

Revenue history (in k)

Filing timeliness

5 of 6 financial statements were filed late (the longest delay 1376 days for 2021).

202521/04/2026
202421/04/2026
202321/04/2026
202221/04/2026
202121/04/2026
202001/02/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 64.80MedianUSD 152.85kAverageUSD 4.86m

Net profit

This companyUSD -439.55MedianUSD -228.23AverageUSD 317.06k

Operating costs

This companyUSD 105.06MedianUSD 187.91kAverageUSD 4.67m

Assets

This companyUSD 9.10kMedianUSD 278.35kAverageUSD 8.47m

Industry

Authorized Representatives

Marek Norbert Zdanowicz – Liquidator

Supervisory board

Aleksander Kiecana – Supervisory Board Member

Monika Tomaszewska Kiecana – Supervisory Board Member

Marek Kiecana – Supervisory Board Member

Ownership

Owner	Shares	Share value	Stake
Centrum Medyczne Biovitalmed sp. z o.o.	1,000	$27,012.43	100%

Beneficial owners

Person	Rights

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication date	Event
May 5, 2026	Call to creditors

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Oasis DiagnosticsS.A.	$282,613.94	oasis-diagnostics.com
NanosanguisS.A.	$192,701.50	nanosanguis.com
Codeit4us Rndsp. z o.o.	$152,435.96	codeit4us.com
VB IdeaP.S.A.	$44,631.63	vbidea.pl
NanovelosS.A.	$24,842.03	nanovelos.com
Bio2materialssp. z o.o.	$14,121.59	bio2materials.com
Nanostalsp. z o.o.	$8,607.48	nanostal.com
IncellvuS.A.	$6,985.93	incellvu.pl
NanotheaS.A.	$115.78	nanothea.com
MolecureS.A.	$10.77	molecure.com

Change history

Date	Event
2026-05-22	Name change (Biovirtus → Biovirtus Spółka Z Ograniczoną Odpowiedzialnością W Likwidacji)
2026-05-22	PKD change (Removed: 70.2, 72.11.Z, 72.19.Z; Added: 72.10.Z, 74.30.Z, 86.96.Z)
2026-04-16	Liquidation opened
2017-02-27	Entered in the register

FAQ

Last updated: 2026-10-07